Laws and Labels: A Regulatory View of Biosimilars

Friday, October 30, 2015
Presented by: 
Erika Lietzan

Now that the first biosimilar product has been approved by FDA, healthcare professionals need to get up to speed on the evolving rules and policies that will separate biosimilars from interchangeable biologics and branded products. Join healthcare legal expert Erika Lietzan for a webinar examining the latest from the FDA on labeling biosimilars, the scientific and legal differences between biosimilars and other products, and the potential impact on prescribing and dispensing practices.

You may also like:

Blog Post

The American Academy of Orthopedic Surgeons (AAOS) has historically recommended antibiotic premedication in select patients with hip or knee implants undergoing medical or dental procedures that produce bacteremia. These individua...

View Blog Post
Blog Post

April is National Minority Health Month. Follow events and discussions at #NMHM17. The theme of the U.S. Department of Health & Human Services’

View Blog Post
Blog Post

Healthcare professionals around the world have been concerned by alarming medical error statistics in recent studies, particularly those involving medications. Errors involving incorrect dosing, dispensing, or administration of me...

View Blog Post

RxPerts Academy

Stay in the Know

Sign up to start receiving notifications via email of our upcoming webinars!

Sign Up